Format

Send to

Choose Destination
Blood. 2010 May 13;115(19):3916-22. doi: 10.1182/blood-2009-10-249367. Epub 2010 Jan 13.

13q14 deletions in CLL involve cooperating tumor suppressors.

Author information

1
Human Cancer Genetics Program and Comprehensive Cancer Center, Department of Molecular Virology, Immunology and Medical Genetics, School of Medicine, Ohio State University, Columbus, OH, USA

Abstract

B-cell chronic lymphocytic leukemia (CLL) is the most common human leukemia. 13q14 deletions are most common chromosomal alterations in CLL. We previously reported that miR-15/16 is a target of 13q14 deletions and plays a tumor suppressor role by targeting BCL2. Because DLEU7 is located near miR-15/16 and is also positioned within a minimal deleted region, we investigated whether DLEU7 could also play a tumor suppressor role. Recent studies of transgenic mouse models demonstrated the importance of the nuclear factor-kappaB (NF-kappaB) pathway in CLL. To examine the possible role of DLEU7 in CLL, we investigated the effect of DLEU7 expression on NF-kappaB and nuclear factor of activated T cells (NFAT) activity. We found that DLEU7 functions as a potent NF-kappaB and NFAT inhibitor by physically interacting and inhibiting TACI and BCMA, members of the tumor necrosis factor (TNF) receptor family involved in B-CLL. In addition, DLEU7 expression in A549 lung cancer cells resulted in a decrease in S phase and increased apoptosis. The results suggest that loss of DLEU7 may cooperate with the loss of miR-15/16 in the pathogenesis of CLL.

Comment in

PMID:
20071661
PMCID:
PMC2869560
DOI:
10.1182/blood-2009-10-249367
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center